Carregant...
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
BACKGROUND: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and increase weight loss efficacy in combination with...
Guardat en:
| Publicat a: | Mol Metab |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8085567/ https://ncbi.nlm.nih.gov/pubmed/33166741 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2020.101109 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|